Ask My Investor AI
Public company · NYSEPublished company research
ONT

Publication identity updated to Onterris, Inc., ticker ONT, effective May 4, 2026; SEC EDGAR confirms CIK 0001643615. The canonical subject ID is preserved to avoid changing the 193-company registry.

Onterris, Inc.

Onterris is an environmental-services company with direct PFAS treatment capability through the former ECT2 platform. Official materials describe selective-resin systems, regeneration and modular treatment, while Q1 2026 revenue was $168.5 million and Consulting and Treatment revenue was $114.6 million. The reviewed sources do not isolate PFAS revenue, so theme materiality remains unresolved and the subject is NOT_READY.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
ONT
Exchange
NYSE
HQ
United States
Currency
USD
SEC CIK
0001643615
Investment case

How this company captures the theme economics

Competitive position

The issuer combines consulting, treatment design, selective resin, on-site regeneration and project delivery. Case studies demonstrate capability, but not recurring PFAS economics or financial materiality.

Scarce assets

Specialized treatment engineering, resin/regeneration know-how, mobile systems and project execution form the direct capability base.

Products, segments, and customers

Onterris realigned its reporting in Q1 2026; Consulting and Treatment generated $114.6 million of quarterly revenue. PFAS work is embedded within broader operations.

Theme capture

Official Onterris materials directly support complex and modular PFAS treatment. Project metrics demonstrate technical capability but do not establish company-level PFAS revenue or margins.

Conditions

What must be true

  1. PFAS treatment awards and installed systems must translate into material recurring revenue or backlog.
  2. Treatment performance and lifecycle economics must remain competitive.

Identifiable catalysts

  • New PFAS treatment awards and disclosed backlog
  • Official PFAS-specific revenue or order disclosure
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Environmental-services and PFAS treatment platform spanning selective resin, modular systems, regeneration and project delivery.

PFAS treatment, destruction and liability transfer

Direct PFAS capability is verified through official treatment pages and case studies. Q1 company and segment figures provide only broad upper bounds; PFAS-specific financial contribution is not disclosed.

Evidence
SEC and issuer sources verify the Onterris identity and current reporting. Official treatment pages and case studies directly support PFAS capability and project performance, not PFAS financial materiality.
Materiality
not assessed — The previously cited 10–15% revenue estimate is not accepted because no reviewed official source directly supports it; PFAS revenue, margins and backlog remain unquantified.
Financial evidence

Official SEC filing evidence

Reference period: Q1 2026.

  • Revenue$168.5 million
    Q1 2026[3]
  • Net loss$12.7 million
    Q1 2026[3]
  • Adjusted EBITDA$17.8 million
    Q1 2026[3]
  • Consulting and Treatment revenue$114.6 million
    Q1 2026[3]
  • Free cash flow-$17.2 million
    Q1 2026[3]

Limitation: Company and segment figures do not isolate PFAS economics. Licensed current valuation is unavailable.

Risks

Material risks and break conditions

Material risks

  • PFAS project timing and regulation can create volatile demand.
  • Technical project results do not ensure financially material recurring revenue.
  • Q1 2026 free cash flow was negative.

Thesis-break conditions

  • Official disclosure shows PFAS is immaterial or unprofitable.
  • Treatment performance, regeneration economics or project execution deteriorates.
Investability conclusion

Where the evidence lands

NOT_READY. Official evidence verifies the updated identity, current scale and direct PFAS capability, but PFAS-specific materiality, licensed current valuation and reviewer acceptance remain unresolved.

Next diligence

  1. Obtain official PFAS-specific orders, backlog, installed-base, revenue and margin evidence.
  2. Connect licensed valuation before human acceptance review.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Onterris, Inc. Q1 2026 Form 10-QSEC EDGAR · primary · published 2026-05-07 · accessed 2026-07-29
  2. Montrose Environmental Group Is Now Onterris (Form 8-K exhibit)SEC EDGAR · primary · published 2026-04-21 · accessed 2026-07-29
  3. Onterris Reports First Quarter ResultsOnterris, Inc. · primary · published 2026-05-07 · accessed 2026-07-29
  4. Complex PFAS Water TreatmentOnterris, Inc. · primary · published undated · accessed 2026-07-29
  5. Modular PFAS Treatment SystemsOnterris, Inc. · primary · published undated · accessed 2026-07-29
  6. Fast-Tracking PFAS Treatment for UtilitiesOnterris, Inc. · primary · published undated · accessed 2026-07-29
  7. Redefining PFOS Treatment for Landfill LeachateOnterris, Inc. · primary · published undated · accessed 2026-07-29